Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Eye cancer, intraocular melanoma
Trial Type:  Treatment
Results 1-24 of 24 for your search:
Start Over
MelmarT Melanoma Margins Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma
Status: Active
Phase: Phase III
Type: Health services research, Treatment
Age: 18 and over
Trial IDs: ANZMTG 03.12, NCI-2016-00246, NCT02385214
Percutaneous Hepatic Perfusion vs Best Alternative Care in Patients With Hepatic-dominant Ocular Melanoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PHP-OCM-301, NCI-2016-00242, NCT02678572
Sym013 (Pan-HER) in Patients With Advanced Epithelial Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: Sym013-01, NCI-2016-01802, NCT02906670
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients with GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Any age
Trial IDs: 05-122, NCI-2016-00874, MSKCC-05122, NCT00445965
Yttrium Y 90 Resin Microspheres in Treating Patients With Uveal Melanoma Who Have Liver Metastases
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10C.95, NCI-2012-00140, 2010-02, NCT01473004
Vorinostat in Treating Patients with Metastatic Melanoma of the Eye
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AAAO5917, NCI-2012-00860, CUMC-IRBAAAO5917, MSKCC-12-027, 9111, 12-027, NCT01587352
Nivolumab and Ipilimumab in Treating Patients with Metastatic Uveal Melanoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2011-0919, NCI-2015-00853, NCI-2012-00665, NCT01585194
Combination Chemotherapy and Tumor Infiltrating Lymphocytes with or without High Dose Aldesleukin in Treating Patients with Metastatic Ocular Melanoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 70
Trial IDs: 13-C-0093, NCI-2013-01586, 130093, P131209, NCT01814046
Epacadostat and Vaccine Therapy in Treating Patients with Stage III-IV Melanoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CITN-04, NCI-2013-01605, NCT01961115
Trametinib with or without GSK2141795 in Treating Patients with Metastatic Uveal Melanoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9445, NCI-2013-02091, 13-144, NCT01979523
Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13P.377, NCI-2014-00338, 2013-047, NCT02068586
Crizotinib following Surgery or Radiation Therapy in Treating Patients with High-Risk Uveal Melanoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-063, NCI-2014-01895, NCI-2015-00689, NCT02223819
Pembrolizumab in Treating Patients with Advanced Uveal Melanoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: VICC MEL 1486, NCI-2015-00020, MEL1486, NCT02359851
Glembatumumab Vedotin in Treating Patients with Metastatic or Locally Recurrent Uveal Melanoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9855, NCI-2015-00159, NCI9855, NCT02363283
Nivolumab with or without Ipilimumab before Surgery in Treating Patients with Stage IIIB-IV Melanoma That Can Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2015-0041, NCI-2015-01520, NCT02519322
Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients with Spine Metastases at Risk for Compressing the Spinal Cord
Status: Active
Phase: Phase II
Type: Natural history/Epidemiology, Treatment
Age: 18 and over
Trial IDs: 2015-0223, NCI-2016-00683, NCT02713269
Sotrastaurin Acetate and Alpelisib in Treating Patients with Metastatic Uveal Melanoma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AAAN4901, NCI-2015-00753, CAEB071AUS01T, NCT02273219
A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IMCgp100-102, NCI-2016-00217, NCT02570308
Selumetinib Sulfate in Treating Patients with Uveal Melanoma That Is Metastatic or Cannot Be Removed by Surgery
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AAAQ6999, NCI-2016-01205, NCT02768766
Ipilimumab and Radiation Therapy in Treating Patients with High-Risk of Recurrence or Locally Advanced Melanoma
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: Pro00045042, NCI-2014-00258, BMS 184-234, NCT01996202
Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MCC-18377, NCI-2016-00358, NCT02652455
Genetic Analysis in Understanding Immunotherapy Resistance in Patients with Stage IIIC-IV Melanoma
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: Pro00059349, NCI-2015-02162, NCT02694965
Pembrolizumab and Stereotactic Radiosurgery in Treating Patients with Melanoma or Non-small Cell Lung Cancer That Has Spread to the Brain
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RAD3179-16, NCI-2016-00718, IRB00086461, NCT02858869
Start Over